Search
Now showing items 1-10 of 19
Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry.
(J Am Heart Assoc, 2013-07-18)
BACKGROUND: The prevalence of atrial fibrillation (AF) continues to increase; however,
there are limited data describing the division of care among practitioners in the
community and whether care differs depending on provider ...
Delays in appropriate antibiotic therapy for gram-negative bloodstream infections: a multicenter, community hospital study.
(PLoS One, 2013)
BACKGROUND: Gram-negative bacterial bloodstream infection (BSI) is a serious condition
with estimated 30% mortality. Clinical outcomes for patients with severe infections
improve when antibiotics are appropriately chosen ...
Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials.
(Psychooncology, 2013-02)
OBJECTIVES: This paper aims to investigate the effect of socioeconomic status, as
measured by education, on the survival of breast cancer patients treated on 10 studies
conducted by the Cancer and Leukemia Group B. METHODS: ...
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
(J Am Heart Assoc, 2013-11-25)
BACKGROUND: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis
in atrial fibrillation. Adoption patterns of this new agent in community practice
are unknown. METHODS AND RESULTS: We studied patterns ...
Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone.
(Bone Marrow Transplant, 2013-11)
Chemotherapy plus G-CSF (C+G) and G-CSF alone are two of the most common methods used
to mobilize CD34(+) cells for autologous hematopoietic SCT (AHSCT). In order to compare
and determine the real-world outcomes and costs ...
Gene expression-based classifiers identify Staphylococcus aureus infection in mice and humans.
(PLoS One, 2013)
Staphylococcus aureus causes a spectrum of human infection. Diagnostic delays and
uncertainty lead to treatment delays and inappropriate antibiotic use. A growing literature
suggests the host's inflammatory response to the ...
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
(Cancer Med, 2013-04)
Patients with unresectable glioblastomas have a poor prognosis, with median survival
of 6-10 months. We conducted a phase II trial of upfront 5-day temozolomide (TMZ)
and bevacizumab (BV) in patients with newly diagnosed ...
A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.
(Cancer Med, 2013-06)
Targeting multiple regulators of tumor angiogenesis have the potential to improve
treatment efficacy. Bevacizumab is a monoclonal antibody directed against vascular
endothelial growth factor and ABT-510 is a synthetic analog ...
Biomarkers to help guide management of patients with pulmonary nodules.
(Am J Respir Crit Care Med, 2013-08-15)
RATIONALE: Indeterminate pulmonary nodules are a common radiographic finding and require
further evaluation because of the concern for lung cancer. OBJECTIVES: We developed
an algorithm to assign patients to a low- or high-risk ...
Gender and age interact to affect early outcome after intracerebral hemorrhage.
(PLoS One, 2013)
BACKGROUND: Intracerebral hemorrhage (ICH) is a common and devastating form of cerebrovascular
disease. In ICH, gender differences in outcomes remain relatively understudied but
have been examined in other neurological ...